Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls

Patients with multiple myeloma are at high risk of severe forms of COVID-19. Despite data showing diminished response to vaccine, the era of highly efficient mRNA vaccine might be a gamechanger. We sought to examine response to mRNA vaccine between healthy controls (n = 28) and multiple myeloma (MM)...

Descripción completa

Detalles Bibliográficos
Autores principales: Bitoun, Samuel, Henry, Julien, Vauloup-Fellous, Christelle, Dib, Nicolas, Belkhir, Rakiba, Mouna, Lina, Joly, Candie, Desjardins, Delphine, Bitu, Marie, Le Grand, Roger, Seror, Raphaèle, Roque Afonso, Anne-Marie, Mariette, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512646/
https://www.ncbi.nlm.nih.gov/pubmed/34645504
http://dx.doi.org/10.1186/s13045-021-01183-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512646/
https://www.ncbi.nlm.nih.gov/pubmed/34645504
http://dx.doi.org/10.1186/s13045-021-01183-2

Ejemplares similares